InterCure

About InterCure

In 1994, brothers Benjamin and Erez Gavish founded InterCure, a company initially rooted in the biomedicine sector. For years, it operated as a holding company, investing in various life science ventures. However, the playbook for InterCure was about to be completely rewritten. The company saw an opportunity in a nascent, but rapidly legitimizing, industry: medical cannabis. A significant transformation began as InterCure shifted its focus, acquiring Canndoc, one of Israel's largest and most established licensed cannabis producers. This move pivoted the entire company. Under the leadership of CEO Alexander Rabinovich, InterCure began to build a vertically integrated "seed-to-sale" operation, controlling everything from cultivation to the distribution of pharmaceutical-grade cannabis products. The company's ambition didn't stop at the Israeli border. A key moment arrived in April 2021 when InterCure merged with Subversive Acquisition LP, a special purpose acquisition company (SPAC). This transaction not only provided significant capital but also paved the way for a listing on the NASDAQ under the ticker 'INCR', giving the Israeli firm access to a global investor base. This strategic move positioned InterCure to execute its international expansion plans, aiming to become a dominant player in the European cannabis market.